PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
L. brownii extracts effectively improved motor dysfunction and increased neurons in the substantia nigra of MPTP-induced Parkinson's disease mice [PMID:39060803].
The classical formula Lily Bulb and Rehmannia Decoction (LBRD) has been clinically applied for two thousand years to treat 'lily disease' (depression) [PMID:30780102].
A specific isospirostanol-type saponin from L. brownii significantly suppressed the proliferation of SMMC-7721 and HepG2 cells in vitro [PMID:38414116].
Evidence summary
PubMed sources
- 1.PMID: 39338404 (2024) — Lilium brownii/Baihe as Nutraceuticals: Insights into Its Composition and Therapeutic Properties. · Pharmaceuticals (Basel, Switzerland)
- 2.PMID: 38634793 (2024) — Two New Phenylpropanoid Compounds from Lilium Brownii and Their Anti-monoamine Oxidase Activity. · Chemistry & biodiversity
- 3.PMID: 39060803 (2024) — Neuroprotective properties of the Lilium brownii extracts in the experimental model of Parkinson's disease. · Metabolic brain disease
- 4.PMID: 39205945 (2024) — Integrated transcriptomic and metabolomic analysis reveals the molecular profiles of dynamic variation in Lilium brownii var. viridulum suffering from bulb rot. · Frontiers in genetics
- 5.PMID: 41368573 (2025)